COVID-19 - June 21, 2021
CureVac reports results from its COVID-19 vaccine trial
CureVac has announced results of the second interim analysis of its international Phase 2b/3 study in approximatively 40,000 subjects (the HERALD study) of CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV. In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy […]
COVID-19 - January 7, 2021
CureVac and Bayer join forces on COVID-19 vaccine candidate
Bayer has signed a collaboration and services agreement with CureVac, a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA). Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac’s COVID-19 vaccine candidate CVnCoV. To this end, Bayer will contribute […]